Skip to main content
Premium Trial:

Request an Annual Quote

Toshiba Enters Biochip Market With Novel Chip to Manage Hepatitis C

NEW YORK, Oct. 18 – Toshiba has entered the biochip arena by developing a DNA chip that it says can help researchers develop individual treatments for patients with hepatitis C, the company said on Thursday. 

The company said it planned to start marketing its pilot SNP-detection chip in fiscal 2002, which kicks off in April. 

Toshiba said the new chip, developed with the GeneCare Research Institute, is designed to help predict the effectiveness of interferon in individual patients. The company also and will help identify of more beneficial treatment regimes. 

Hepatitis C attacks the liver and infects roughly two million people in Japan and 170 million worldwide, according to Toshiba. The disease is chronic and can lead to cirrhosis, liver cancer, and death. 

The teatment record for interferon, a standard treatment for the disease, has ranged from highly efficacious to downright dangerous, outcomes that are tied to specific doses of the drug. Toshiba said its biochip will help indicate progressive doses of interferon for patients who responded well to it. 

DNA chips have not become a widely used diagnostic tool because they require large and expensive equipment. But the current method for detection, for which Toshiba holds fundamental patents, will allow a small system to be created and used at a lower cost, the company said. 

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.